Drug watchdog: Year-Long safety check for lung cancer pill
NCT ID NCT05100069
Summary
This study is monitoring the safety of the lung cancer drug Alunbrig (brigatinib) in real-world use in Japan. It will follow 500 patients with a specific advanced lung cancer for one year to track side effects, with a special focus on lung-related problems. The goal is to gather more information on the drug's safety profile in everyday clinical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda Selected Site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.